The Pharma Data

SEPTEMBER 29, 2020

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas. At the time, Pfizer made a $33m equity investment in Sosei as part of the collaboration agreement.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Clinical Trials Small Molecule Pharma Companies 52

Dark Matter Blog

JUNE 21, 2023

Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

Dark Matter Blog

JULY 19, 2021

Arrakis has gone through many significant transitions since its founding in 2015. Or should I say back to retirement, as he was comfortably relaxing at home back in 2016 when Jen Petter lured him back into the fray with the siren call of developing a new class of RNA-targeted small-molecule medicines here at Arrakis.

Small Molecule 52

Small Molecule RNA Science Therapies 52

Dark Matter Blog

JULY 19, 2021

Back in 2015, I felt compelled to set out in a new direction in drug discovery. However, in June I happened to attend the Gordon Research Conference on Chemical Biology and High-throughput Chemistry where I saw a session on small molecules and RNA. I was in my third year as VP of Chemistry for Celgene. This is a thing?

RNA 52

RNA Small Molecule Science Therapies 52

Drug Target Review

JUNE 12, 2023

The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

JULY 15, 2021

Founded in 2015 and based in Pasadena, California, Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body. About Protomer Technologies Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body to automatically activate as needed.

Small Molecule 52

Small Molecule Engineering Therapies Science 52

The Pharma Data

OCTOBER 25, 2020

Vatiquinone, developed from PTC’s Bio-e platform, is an investigational oral small molecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways underpinning many neurological disease pathologies, including epilepsy. 2015; Chevallier et al. Annals of Neurology.2015;

Clinical Trials 52

Clinical Trials Trials Small Molecule Regulations 52

PLOS: DNA Science

SEPTEMBER 5, 2024

Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division. A name ending in “nib” means a small molecule that inhibits an enzyme called a kinase, and is short for “inhibit.”

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

DrugBank

AUGUST 15, 2024

This drug, approved by the FDA in 2015, targets a protein that regulates cholesterol levels in the blood, offering a novel therapeutic approach for patients who do not respond adequately to statins.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

Agency IQ

NOVEMBER 10, 2023

BY ALEXANDER GAFFNEY, MS, RAC | NOV 9, 2023 6:35 PM CST Background on CDER’s Office of Pharmaceutical Quality (OPQ) CDER’s Office of Pharmaceutical Quality became operational in January 2015, making it a still relatively recent addition to the agency. However, there’s not much information available regarding the reorganization just yet.

Pharmaceuticals 40

Pharmaceuticals Small Molecule Science FDA 40

The Pharma Data

OCTOBER 27, 2020

million in 2015. Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer. The $71 million funding includes an initial financing of $32.5 In the U.S., Primmune Therapeutics . The company’s $27.4

Small Molecule 52

Small Molecule Immune Response Therapies Clinical Development 52

Molecule Blog

AUGUST 13, 2021

This program focuses on testing and developing three of these small molecules as possible interventions in ageing. These molecules target the longevity field with the aim of letting everyone live healthier, happier and longer lives.

FDA Approval 52

FDA Approval DNA Small Molecule FDA 52

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. Nasdaq GILD) and Arcus Biosciences,Inc.

Research 52

Research Clinical Development Small Molecule Packaging 52

The Pharma Data

NOVEMBER 29, 2020

” “The emergence of the PROTAC technology represents another breakthrough in the identification of small molecule drugs. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. 2015, 58 , 1038?1052. Aguilar, A.; Bernard, D.;

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

SEPTEMBER 15, 2020

In a revolution of therapeutic approaches, Trilomer® peptidomimetic binders combine the cell permeability and degradation resistance of small molecules with the large surface area of antibodies, allowing them to target both intracellular and extracellular targets.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

NIH Director's Blog: Drug Development

JULY 20, 2017

The next major milestone on the therapeutic pathway was the FDA’s approval in 2015 of Orkambi, a drug that combines ivacaftor with lumacaftor, the first “corrector”. That combination therapy was designed to help CF patients with two copies of the F508del mutation.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

The Pharma Data

JANUARY 11, 2021

is a value-oriented investment manager founded in 2015 and based in Singapore. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. About 3D Investment Partners. MediciNova, Inc.

Clinical Trials 52

Clinical Trials Trials Small Molecule Vaccine 52

New Drug Approvals

SEPTEMBER 13, 2024

18] In February 2015, Cerecor Inc. “LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders” Neuropharmacology. 11 December 2015. February 20, 2015. Retrieved March 18, 2015.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Metabolite Tales Blog

MAY 12, 2023

In 2022, fewer of the 19 newly FDA approved small molecule drugs contained F atoms (adagrasib, lenacapavir, oteseconazole, vonoprazan), but this was followed by 3 more approvals of F-containing drugs in the first quarter of 2023 alone (pirtobrutinib, omaveloxolone, leniolisib). Blackaby, Alastair J. Lyssikatos, Peter W.

Drugs 52

Drugs Small Molecule Metabolic Stability FDA Approval 52

Codon

MARCH 19, 2024

When a somatic cell is reprogrammed into an iPSC, either by using Yamanaka’s method or small molecules that mimic the four proteins, the epigenomes of the reprogrammed cells are effectively “wiped clean” and reverted into a state comparable to that of an embryonic stem cell. Credit: PA Images / Alamy.

DNA 55

DNA Small Molecule Regulations Laboratories 55

Codon

AUGUST 27, 2024

Extra pieces of data, including proteins, lipids, or small molecules, are helpful when a particular DNA sequence is difficult to amplify or isolate from a sample, or when sequencing results don’t point squarely at a single disease-causing organism. But DNA alone is not always enough to identify a pathogen.

DNA 83

DNA Laboratories Hospitals Virus 83

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Our long-time clinical development lead, Bhaskar Srivastava, an M.D.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

NIH Director's Blog: Drug Development

APRIL 7, 2015

After a whirlwind tour of the cutting-edge robotics facility for high throughput screening of small molecules, she joined me and NCATS Director Dr. Chris Austin in announcing that, thanks to an innovative public-private partnership, an experimental drug originally developed to fight cancer is now showing promise against Alzheimer’s disease.

Disease 40

Disease Drugs Clinical Trials Small Molecule 40

Codon

JUNE 11, 2024

Small molecules can randomly transit through the pore and create disruptions, and the polymerase ratchet mechanism is imperfect, occasionally causing DNA to temporarily reverse direction through the pore. In 2015, Oxford Nanopore spun off another company, Metrichor , to provide base-calling algorithms through a web interface.

DNA 73

DNA Engineering RNA Small Molecule 73

The Pharma Data

OCTOBER 26, 2020

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. 2015:32(6):409-420. Pfizer recently announced results from the fourth trial in the JADE global development program, JADE TEEN. Additional data from other studies in the JADE program will be presented and published in the coming months.

FDA 40

FDA Clinical Trials Trials Therapies 40

Codon

MAY 30, 2023

Read Programming inactive RNA-binding small molecules into bioactive degraders. Malaria deaths plummeted between 2010 and 2015, thanks mostly to the billions of dollars in philanthropic funding that were used to purchase bed nets and medicines. Molecular Therapy. Nature Communications. ACS Synthetic Biology. eClinicalMedicine.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

Read Programming inactive RNA-binding small molecules into bioactive degraders. Malaria deaths plummeted between 2010 and 2015, thanks mostly to the billions of dollars in philanthropic funding that were used to purchase bed nets and medicines. Molecular Therapy. Nature Communications. ACS Synthetic Biology. eClinicalMedicine.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

FEBRUARY 4, 2021

Imbruvica was approved as a monotherapy for WM in 2015 and as a combination therapy with rituximab in 2018 based on the iNNOVATE primary analysis. AbbVie and Frontier Medicines, Corp.,

Production 52

Production Clinical Trials International Small Molecule 52

Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This workshop built on three prior workshops held by the FDA-AACR, which took place in 2015, 2016 and 2017.

Science 40

Science FDA Trials Clinical Pharmacology 40

Agency IQ

DECEMBER 11, 2023

In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules. Dose optimization for oncology products has been an issue flagged for improvement even prior to the creation of OCE.

FDA 40

FDA Science Clinical Trials Trials 40

Drug Target Review

JANUARY 5, 2024

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays. Journal of Biological Chemistry 298(8), 102167 (2022).

Small Molecule 59

Small Molecule Drugs Biochemical Assays Regulations 59

The Premier Consulting Blog

APRIL 25, 2023

In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA. Summary basis of approval (SBA) for Aristada (NDA 207533, 10/5/2015), [link] [accessed 23 March 2023]. ICH Harmonised Guideline S1B(R1): Testing for carcinogenicity of pharmaceuticals.

FDA 52

FDA Animal Testing Pharmacokinetics Small Molecule 52

The Pharma Data

OCTOBER 14, 2020

Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015. has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. Dolmatics – U.K.-based based Dotmatics Ltd.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

The Pharma Data

JULY 21, 2021

Pfizer and Biovac have worked together since 2015 on the sterile formulation, fill, finish and distribution of the Prevenar 13 vaccine. To date, Pfizer and BioNTech have shipped more than 1 billion COVID-19 vaccine doses to more than 100 countries or territories in every region of the world.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

New Drug Approvals

JULY 10, 2023

Zavegepant is a highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, with potential analgesic and immunomodulating activities. The clinical trial is expected to complete in September 2020. Migraine is both widespread and disabling. New Haven, CT.

Clinical Trials 40

Clinical Trials Treatment FDA Trials 40